Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care:: a multicentre, randomized, double-blind, controlled trial

被引:251
作者
Guyonnet, D.
Chassany, O.
Ducrotte, P.
Picard, C.
Mouret, M.
Mercier, C.-H.
Matuchansky, C.
机构
[1] Danone Res, F-91767 Palaiseau, France
[2] Dept Rech Clin, AP HP, Paris, France
[3] Univ Rouen Hosp, IFRMP23, EA 3234, Digest Tract Res Grp, Rouen, France
[4] Umanis Clin Res, F-92300 Levallois Perret, France
[5] Univ Paris 07, Lariboisierer St Louis Fac Med, F-75221 Paris 05, France
关键词
D O I
10.1111/j.1365-2036.2007.03362.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Health-related quality of life (HRQoL) has been rarely evaluated as a primary endpoint in the assessment of the effect of probiotics on the irritable bowel syndrome (IBS). AimTo study the effects of fermented milk containing Bifidobacterium animalis DN-173 010 and yoghurt strains on the IBS in a multicentre, double-blind, controlled trial. Methods A total of 274 primary care adults with constipation-predominant IBS (Rome II) were randomized to consume for 6 weeks either the test fermented milk or a heat-treated yoghurt (control). HRQoL and digestive symptoms were assessed after 3 and 6 weeks on an intention-to-treat population of 267 subjects. Results The HRQoL discomfort score, the primary endpoint, improved (P < 0.001) in both groups at weeks 3 and 6. The responder rate for the HRQoL discomfort score was higher (65.2 vs. 47.7%, P < 0.005), as was the decrease in bloating score [0.56 +/- (s.d.)1.01 vs. 0.31 +/- 0.87, P = 0.03], at week 3 in the test vs. the control group. In those subjects with < 3 stools/week, stool frequency increased (P < 0.001) over 6 weeks in the test vs. control group. Conclusions This study suggests a beneficial effect of a probiotic food on discomfort HRQoL score and bloating in constipation-predominant IBS, and on stool frequency in subjects with < 3 stools/week.
引用
收藏
页码:475 / 486
页数:12
相关论文
共 64 条
[21]   Intestinal gas distribution determines abdominal symptoms [J].
Harder, H ;
Serra, J ;
Azpiroz, F ;
Passos, MC ;
Aguadé, S ;
Malagelada, JR .
GUT, 2003, 52 (12) :1708-1713
[22]   Systematic review: the economic impact of irritable bowel syndrome [J].
Inadomi, JM ;
Fennerty, MB ;
Bjorkman, D .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (07) :671-682
[23]  
Irvine EJ, 2006, GASTROENTEROLOGY, V130, P1538, DOI 10.1053/j.gastro.2005.11.058
[24]   DETERMINING A MINIMAL IMPORTANT CHANGE IN A DISEASE-SPECIFIC QUALITY-OF-LIFE QUESTIONNAIRE [J].
JUNIPER, EF ;
GUYATT, GH ;
WILLAN, A ;
GRIFFITH, LE .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1994, 47 (01) :81-87
[25]   EFFECT SIZES FOR INTERPRETING CHANGES IN HEALTH-STATUS [J].
KAZIS, LE ;
ANDERSON, JJ ;
MEENAN, RF .
MEDICAL CARE, 1989, 27 (03) :S178-S189
[26]   A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating [J].
Kim, HJ ;
Roque, MIV ;
Camilleri, M ;
Stephens, D ;
Burton, DD ;
Baxter, K ;
Thomforde, G ;
Zinsmeister, AR .
NEUROGASTROENTEROLOGY AND MOTILITY, 2005, 17 (05) :687-696
[27]   A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome [J].
Kim, HJ ;
Camilleri, M ;
McKinzie, S ;
Lempke, MB ;
Burton, DD ;
Thomforde, GM ;
Zinsmeister, AR .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (07) :895-904
[28]   Abnormal colonic fermentation in irritable bowel syndrome [J].
King, TS ;
Elia, M ;
Hunter, JO .
LANCET, 1998, 352 (9135) :1187-1189
[29]   Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation [J].
Koebnick, C ;
Wagner, I ;
Leitzmann, P ;
Stern, U ;
Zunft, HJF .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2003, 17 (11) :655-659
[30]   The challenge of subgroup analyses - Reporting without distorting [J].
Lagakos, SW .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (16) :1667-1669